

1 **Severity of Prior COVID-19 Infection is Associated with Postoperative** 2 **Outcomes Following Major Inpatient Surgery**

3 Nathaniel B. Verhagen¹, Gopika SenthilKumar^{1,2}, Taylor Jaraczewski¹, Nicolas K.
4 Koerber¹, Jennifer R. Merrill¹, Madelyn A. Flitcroft¹, Aniko Szabo³, Anjishnu Banerjee³,
5 Xin Yang⁴, Bradley W. Taylor⁴, Carlos E. Figueroa Castro⁵, Tina W.F. Yen¹, Callisia N.
6 Clarke¹, Kathryn Lauer⁶, Kurt J. Pfeifer⁷, Jon C. Gould⁸, Anai N. Kothari^{1,4}; on behalf of
7 the N3C Consortium

8 ¹Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin,
9 Milwaukee, WI

10 ²Department of Physiology and Anesthesiology, Medical College of Wisconsin,
11 Milwaukee, WI

12 ³Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI

13 ⁴Clinical and Translational Science Institute of Southeastern Wisconsin, Medical College
14 of Wisconsin, Milwaukee, WI

15 ⁵Department of Medicine, Division of Infectious Diseases, Medical College of Wisconsin,
16 Milwaukee, WI

17 ⁶Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI

18 ⁷Department of Medicine, Section of Perioperative & Consultative Medicine, Medical
19 College of Wisconsin, Milwaukee, WI

20 ⁸Department of Surgery, Division of Minimally Invasive and GI Surgery, Medical College
21 of Wisconsin, Milwaukee, WI
22

23 24 **Corresponding Author:**

25 Anai N. Kothari, MD MS FSSO
26 Medical College of Wisconsin
27 Division of Surgical Oncology
28 8701 W Watertown Plank Road
29 Milwaukee, Wisconsin 53226, USA
30 (414)955-1443
31 akothari@mcw.edu

32 **ABSTRACT**

33 **Objective:** To determine the association between severity of prior history of SARS-
34 CoV-2 infection and postoperative outcomes following major elective inpatient surgery.

35 **Summary Background Data:** Surgical guidelines instituted early in the COVID-19
36 pandemic recommended delay in surgery up to 8 weeks following an acute SARS-CoV-
37 2 infection. Given that surgical delay can lead to worse medical outcomes, it is unclear if
38 continuation of such stringent policies is necessary and beneficial for all patients,
39 especially those recovering from asymptomatic or mildly symptomatic COVID-19.

40 **Methods:** Utilizing the National Covid Cohort Collaborative (N3C), we assessed
41 postoperative outcomes for adults with and without a history of COVID-19 who
42 underwent major elective inpatient surgery between January 2020 and February 2023.
43 COVID-19 severity and time from SARS-CoV-2 infection to surgery were each used as
44 independent variables in multivariable logistic regression models.

45 **Results:** This study included 387,030 patients, of which 37,354 (9.7%) had a diagnosis
46 of preoperative COVID-19. History of COVID-19 was found to be an independent risk
47 factor for adverse postoperative outcomes even after a 12-week delay for patients with
48 moderate and severe SARS-CoV-2 infection. Patients with mild COVID-19 did not have
49 an increased risk of adverse postoperative outcomes at any time point. Vaccination
50 decreased the odds of mortality and other complications.

51 **Conclusions:** Impact of COVID-19 on postoperative outcomes is dependent on
52 severity of illness, with only moderate and severe disease leading to higher risk of
53 adverse outcomes. Existing wait time policies should be updated to include
54 consideration of COVID-19 disease severity and vaccination status.

55 INTRODUCTION

56 As of February 2023, over 100 million cases of SARS-CoV-2 infections have been
57 reported in the US¹. Among those with prior infection, 15–20% will require elective
58 surgery². Prior history of COVID-19 infection is associated with adverse postoperative
59 outcomes and complications³⁻⁶, and this risk can persist up to eight weeks after
60 infection⁵. Accordingly, early in the pandemic, several groups recommended a delay in
61 surgery for 7–8 weeks following a COVID-19 infection^{5,7}.

62 While these guidelines attempted to mitigate the risk of COVID-19 by delaying surgery,
63 as the pandemic transitions to an endemic phase, there is a paucity of data to guide the
64 de-implementation of these policies. This is especially important when also considering
65 that delaying care can worsen both short- and long-term health outcomes⁸. In addition,
66 delayed surgical care can lead to prolonged poor quality of life including chronic pain,
67 impaired mobility, and inability to work.

68 The severity of a SARS-CoV-2 infection can vary widely from mild flu-like symptoms or
69 no symptoms to systemic disease requiring hospitalization and even critical care. Most
70 current guidelines for managing COVID-19 in the perioperative setting are not stratified
71 by disease severity; however, there appears to be a relationship between severity of
72 infection and postoperative outcomes⁸. Prior studies also show that compared to those
73 with asymptomatic or mild disease, postoperative intensive care unit stay is higher
74 among those with severe COVID-19 who require hospitalization⁹. This suggests that
75 including severity of SARS-CoV-2 infection in surgical wait time guidelines may facilitate
76 more personalized patient recommendations and prevent unnecessary delays to

77 surgery for those with less severe infections. In addition, since disease severity can be
78 lowered through vaccination², and as of February 2023, over 269 million people in the
79 US received at least 1 dose of COVID-19 vaccine¹, the impact of preoperative
80 vaccination among patients who present with COVID-19 prior to requiring surgery must
81 be taken into consideration.

82 The primary objective of this study was to measure the association between the severity
83 of SARS-CoV-2 infection prior to major elective surgery and postoperative adverse
84 outcomes. Secondary objectives included investigating how severity should be
85 considered in surgical wait time guidelines and the influence of vaccination on
86 postoperative outcomes.

87 **METHODS**

88 Electronic health record data from the National COVID Cohort Collaborative (N3C), the
89 largest multi-site centralized data source of COVID-19 patients in the United States,
90 was retrospectively analyzed using the N3C Data Enclave. PCORnet, TriNetX, OMOP,
91 and ACT are the primary data sources that contribute to N3C. A detailed description of
92 the N3C's rationale, design, infrastructure, and deployment has been previously
93 reported. Patients 18 years and older who underwent major inpatient surgery between
94 January 2020 and February 2023 were included, and the surgical procedures were
95 selected based on prior literature assessing the role of COVID-19 on surgical
96 outcomes⁵. The following were included: hip arthroplasty, knee arthroplasty,
97 laminectomy, spinal arthrodesis, craniectomy, aortic aneurysm repair, lung excision,

98 coronary artery bypass graft, esophagectomy, mastectomy, prostatectomy, colectomy,
99 gastrectomy, hepatectomy, and pancreatectomy (Supplemental Table 1).

100 Patient characteristics (sex, age, race and ethnicity, Charlson Comorbidity Index)¹¹,
101 were identified using the N3C's Shared Knowledge Store patient fact table. Standard
102 SNOMED codes from the Observational Health Data Science and Informatics' (OHDSI)
103 ATLAS tool were used to identify elective inpatient procedures and patients'
104 comorbidities (Supplemental Table 1,2). Exclusion criteria included undergoing natural
105 orifice, percutaneous, endoscopic, diagnostic (unless open surgery), or transplant
106 procedures. For patients with multiple surgeries, the first surgery after SARS-CoV-2
107 infection was used.

108 COVID-19 positivity was defined as having a positive lab measurement (PCR or
109 antigen) or a positive COVID-19 diagnosis (ICD10-CM code U07.1) any time before
110 surgery. Patients with COVID-19 within 24 hours of surgery were excluded. The severity
111 of a patient's COVID-19 was determined using the World Health Organization's (WHO)
112 Clinical Progression Scale (CPS)¹¹. Patient-specific severity was obtained from the N3C
113 Knowledge Store and derived from critical visits associated with COVID positivity. Mild
114 severity was defined as having outpatient visit only (WHO Severity 1–3). Moderate
115 severity was defined as requiring hospitalization without pulmonary support (WHO
116 Severity 4–6). Severe disease was defined as needing hospitalization with
117 extracorporeal membrane oxygenation (ECMO or invasive ventilation, WHO Severity 7–
118 9)¹². The N3C Knowledge Store was used to determine the vaccination status of
119 patients. Fully vaccinated patients were defined as having either received a single dose
120 of the viral vector vaccine or two doses of mRNA vaccine at least 14 days before their

121 first SARS-CoV-2 infection. Patients who received only one dose of the mRNA vaccine
122 or were vaccinated after a COVID-19 diagnosis were not considered fully vaccinated.

123 The primary outcome of the study was a 30-day composite adverse postoperative event
124 and included the following: mortality, unplanned readmission, acute myocardial
125 infarction, cardiac arrhythmia, deep vein thrombosis, pneumonia, pulmonary embolism,
126 renal failure, respiratory failure, sepsis, and urinary tract infection. Each individual 30-
127 day complication included in the composite outcome was also separately evaluated.
128 Outcomes were constructed using SNOMED codes and concepts associated with
129 chronic conditions or directly caused by COVID-19 were excluded (Supplemental Table
130 3).

131 Unadjusted baseline characteristics and comparisons between patients with and without
132 prior COVID-19 were analyzed using standard descriptive statistics. Adjusted analyses
133 were performed using multivariable logistic regression models. Separate models were fit
134 for each outcome with covariates that included age, sex, race and ethnicity, Charlson
135 Comorbidity Index (CCI), and relative surgical risk. Relative surgical risk is a computed
136 feature based on the expected median length of stay for a given procedure. Additional
137 logistic regression models were fit to measure the association between 30-day
138 postoperative adverse outcomes and (1) time between SARS-CoV-2 infection and
139 surgery, (2) disease severity, and (3) vaccination status. Within each disease severity
140 group, the risk of 30-day postoperative adverse outcomes as a factor of time between
141 infection and surgery was analyzed. All analysis were conducted using the N3C Data
142 Enclave using the tidyverse, ggplot2, gtsummary, splines, and broom R packages.

143 **RESULTS**

144 387,030 patients were included in the study and 37,354 (9.7%) had a preoperative
145 diagnosis of COVID-19. Table 1 details baseline patient demographics and
146 characteristics in those with and without a history of COVID-19.

147 *History of COVID-19 and 30-day postoperative adverse outcomes*

148 On unadjusted analysis, rate of 30-day postoperative adverse events was greater in
149 patients with a history of COVID-19 than those without (22.7% vs. 21.5%, $P<0.001$,
150 Table 1). Additionally, the rates of 30-day mortality (1.8% vs. 1.4%), postoperative
151 pulmonary embolism (1.4% vs. 1.2%; $P=0.008$), renal failure (6.9% vs. 6.4%; $P<0.001$),
152 sepsis (3.2% vs. 2.9%; $P=0.007$), and composite non-fatal event (22% vs. 21%;
153 $P<0.001$) were all significantly greater in patients with a history of COVID-19 (Table 1).
154 Following adjustment for age, sex, race, ethnicity, smoking status, comorbid disease,
155 and relative risk of surgery, patients with a history of COVID-19 had greater odds of 30-
156 day composite adverse postoperative events (aOR 1.09 [1.06–1.12]; Figure 1).

157 *Association of time between SARS-CoV-2 infection and surgery and 30-day* 158 *postoperative adverse outcomes*

159 Patients were stratified based on timing of surgery relative to SARS-CoV-2 infection.
160 Groups included 0–4 weeks ($N=7,425$, 19.9%), 4–8 weeks ($N=3,936$, 10.5%), 8–12
161 weeks ($N=2,604$, 7.0%) and 12+ weeks ($N=23,389$, 62.6%). Patients who underwent
162 surgery 0–4 weeks after COVID-19 had overall higher rates of postoperative adverse
163 events, including mortality (3.3% vs. 1.4%; $P<0.001$) and any non-fatal complications

164 (26% vs. 21%, $P < 0.001$), when compared to patients without COVID-19 (Supplemental
165 Table 4). On adjusted analysis (Figure 2, Supplemental Table 5), patients who
166 underwent surgery within 4 weeks of SARS-CoV-2 infection had increased odds of 30-
167 day postoperative composite adverse event (aOR 1.27 [1.20–1.35]), mortality (aOR
168 2.34 [2.05–2.67]), deep vein thrombosis (aOR 1.33 [1.12–1.57]), pneumonia (aOR 1.60
169 [1.43–1.79]), pulmonary embolism (aOR 1.44 [1.20–1.70]), renal failure (aOR 1.28
170 [1.17–1.39]), respiratory failure (aOR 1.53 [1.40–1.66]), and sepsis (aOR 1.52 [1.36–
171 1.69]). The odds of composite adverse postoperative outcome returned to baseline at
172 12 weeks following infection (aOR 1.01 [0.98–1.05] at 12+ weeks).

173 *Association of severity of SARS-CoV-2 infection and 30-day postoperative adverse*
174 *outcomes*

175 Patients were next stratified based on the severity of their SARS-CoV-2 infection prior to
176 surgery, and 31,677 (84.8%), 5,009 (13.4%), and 655 (1.8%) patients had mild,
177 moderate, and severe disease, respectively. Incidence of adverse 30-day postoperative
178 outcomes increased with severity across all measured outcomes (Supplemental Table
179 6), and patients with severe disease had the highest rate of mortality (14% vs. 1.4%),
180 any non-fatal complication (60% vs. 21%), and hospital readmission (18% vs. 11%)
181 when compared to patients without COVID-19 history ($P < 0.001$ all). After adjusting for
182 patient demographics, risk of surgery, and comorbidities, patients with moderate and
183 severe disease had higher odds for all assessed adverse events except for pulmonary
184 embolism for moderate COVID-19 (aOR 1.19 [0.96–1.45]) and hospital readmission for
185 severe COVID-19 (aOR 1.20 [0.98–1.46]) (Figure 3, Supplemental Table 7).

186 *The interplay between timing of surgery and COVID-19 disease severity in influencing*
187 *risk for 30-day composite postoperative complications*

188 For each COVID-19 severity group (mild, moderate, severe), the adjusted odds of
189 having a composite adverse postoperative event were measured (Figure 4). Patients
190 with mild COVID-19 infections did not demonstrate an increased risk, regardless of the
191 time between infection and surgery. Patients with moderate disease were observed to
192 have increased risk for composite adverse events at 0–4 weeks (aOR 1.84 [1.61–2.10])
193 that persisted beyond 12 weeks between COVID-19 and surgery (aOR 1.36 [1.25–
194 1.48]) when compared to patients without prior history of COVID-19. The magnitude of
195 risk was greater for patients with severe disease, with highest odds for an adverse
196 event occurring if surgery was performed within 4 weeks of SARS-CoV-2 infection (aOR
197 8.41 [6.42–11.1]). This risk did decrease with time, though it remained elevated when
198 compared to patients who did not have prior COVID-19 (aOR 2.22 [1.66–2.95] at 12+
199 weeks).

200 *Preoperative vaccination and 30-day postoperative adverse outcomes*

201 In patients with COVID-19 prior to surgery, vaccination significantly decreased rates of
202 pneumonia (2.3% vs. 3.0%; $P=0.003$), respiratory failure (4.2% vs. 5.6%; $P<0.001$), and
203 sepsis (2.7% vs. 3.3%; $P<0.05$) (Supplemental Table 8). After adjustment for patient
204 demographics, comorbidities, and relative risk of surgery, vaccination was associated
205 with decreased odds of mortality (aOR 0.76 [0.59–0.95]), pneumonia (aOR 0.73 [0.60–
206 0.88]), respiratory failure (aOR 0.72 [0.62–0.83]), and sepsis (aOR 0.79 [0.66–0.94])
207 (Figure 5).

208 **DISCUSSION**

209 In this study, we aimed to understand how the severity of a SARS-CoV-2 infection prior
210 to major elective inpatient surgery influences postoperative outcomes using the N3C
211 Data Enclave—a harmonized electronic health data platform comprising over 70
212 institutions and more than 18,000,000 patients¹⁰. Our findings demonstrate that a prior
213 history of COVID-19 is an independent risk factor for adverse surgical outcomes, and
214 the risk remains elevated for 12 weeks after a SARS-CoV-2 infection; however, this is
215 dependent on the severity of COVID-19. Patients with mild disease (not requiring
216 hospitalization) did not have an elevated risk of adverse outcomes regardless of the
217 timing of surgery. Those with moderate and severe disease had persistently elevated
218 surgical risk that lasted 12+ weeks after an acute infection.

219 The results of this study are consistent with prior work examining surgical outcomes in
220 patients with a history of SARS-CoV-2 infection conducted early in the pandemic. The
221 COVIDSurg Collaborative, a multinational collaborative that aimed to explore the impact
222 of COVID-19 in surgical patients and services, published the first population-level study
223 assessing surgical outcomes following a SARS-CoV-2 infection. They found an
224 increased risk of surgical mortality that lasted for 7 weeks following an acute infection⁷.
225 Another large-scale study by Deng and colleagues confirmed these findings in a United
226 States population and advocated for a wait time of 8 weeks from the time of a SARS-
227 CoV-2 infection before proceeding with elective surgery⁵. In response to these data
228 (and other similar findings from single institution series), expert guidelines suggested
229 delaying elective surgery 7 weeks while weighing the time-sensitivity of the
230 intervention¹³. These studies and guidelines were crucial given the novel situation

231 perioperative providers were faced with early in the COVID-19 pandemic as an
232 increasing number of patients with prior SARS-CoV-2 infection required elective
233 surgery.

234 Still, several gaps remain in the evidence base for guiding the management of this
235 patient population which are now addressed by this study. We re-demonstrate the risk
236 for adverse 30-day composite postoperative outcomes remains elevated for 8 weeks
237 after a SARS-CoV-2 infection; however, when stratified by severity, this risk only is
238 present in those recovered from moderate and severe infections (anyone who required
239 hospitalization). Those with mild disease were not at increased risk of composite
240 adverse outcomes even when undergoing surgery within 4 weeks of an acute infection
241 which is consistent with prior work⁸. We also provide a more detailed measurement of
242 the association across a spectrum of specific postoperative complications. For example,
243 patients with mild disease had no increased odds for all assessed adverse events,
244 moderate disease showed elevated risk for all assessed complications, while those with
245 severe disease had increased odds of all assessed complications with a magnitude of
246 effect multiple-fold greater. This study also provides evidence that vaccination can
247 reduce the risk of adverse postoperative events in patients with a prior history of
248 COVID-19.

249 The data presented in this study include patients who underwent surgery prior to March
250 2023 and thus reflects the current environment as the pandemic shifts to an endemic
251 phase. As a comparison, data collected for the COVIDSurg study was in October of
252 2020, and the Deng et al. study of patients in the United States included surgeries
253 performed until June of 2021. Equipped with the updated data presented in this study,

254 we propose the following guidance for managing patients prior to inpatient elective
255 surgery. First, all patients who are planned to undergo surgery should be assessed for
256 their history of COVID-19, including detailed information regarding the severity of their
257 infection. Those with a prior history should be classified as having either
258 asymptomatic/mild disease or moderate/severe disease. After this determination is
259 made, patients with asymptomatic/mild disease should have their surgery delayed at
260 least 5 days from the time of positive test to ensure they do not develop progressive
261 symptoms that increase the severity of illness. If they remain asymptomatic/mild after
262 this wait time, our data supports the safety of proceeding with elective surgery.
263 However, if the patient has moderate/severe disease or develops moderate/severe
264 disease, then consideration should be made for delaying surgery while also considering
265 the risk/benefit ratio of potential harms related to a prolonged delay in circumstances of
266 time-sensitive surgical indications. Since we do not observe a return to baseline risk
267 even beyond 12 weeks in patients with moderate/severe disease, no standard time for
268 delay can be recommended. Instead, we advocate for early engagement with
269 perioperative medicine teams and/or dedicated long COVID clinics to identify strategies
270 for optimal risk reduction and provide objective assessment of physiologic recovery prior
271 to proceeding with surgery. At our institution, all patients with a history of
272 moderate/severe disease are recommended to be referred to preoperative clinic for
273 assessment prior to procedure to assess for recovery and help collaboratively
274 determine the optimal timing for surgery. Developing and applying machine
275 learning/artificial intelligence tools using the N3C Data Enclave are active areas of work

276 in our group to help provide more specific guidance for patients with a history of
277 moderate or severe SARS-CoV-2 infection.

278 There are several limitations to our study that must be carefully considered when
279 interpreting the results. The use of electronic health record data within N3C Data
280 Enclave may introduce biases that are well-described in prior studies¹⁴. Methods
281 specific to N3C can help manage several of these through rigorous data
282 standardization, a highly engaged user community, and a centralized platform for
283 handling all data-related tasks including extraction, processing, and analyses. Another
284 source of bias is the selection of patients to undergo surgery after recovering from a
285 prior COVID-19 infection. Detailed information on preoperative evaluation, indications,
286 and rationale for proceeding with surgery prior to 7 weeks in patients with prior COVID-
287 19 is not available. Additionally, we were unable to directly measure the association
288 between SARS-CoV-2 variants and outcomes—though, this likely is indirectly
289 accounted for in analyses that include severity. Despite these potential shortcomings,
290 leveraging the largest COVID-19-specific national data provides a unique opportunity to
291 help guide the management of patients with previous SARS-CoV-2 infections
292 undergoing elective surgery.

293 In conclusion, prior COVID-19 infection is a risk factor for adverse postoperative
294 outcomes following major inpatient elective surgery. The magnitude and duration of this
295 risk is dependent on the severity of COVID-19 infection and is reduced in vaccinated
296 patients. As the pandemic transitions to an endemic phase, the results of this study
297 emphasize a one-sized-fits-all approach to risk stratification in this patient population

298 can lead to unnecessary surgical delays, and consensus guidelines should be updated
299 to include consideration of COVID-19 disease severity and vaccination status.

300

301

302

303

304

305

306

307

308

309

310 REFERENCES

- 311 1. Johns Hopkins Coronavirus Resource Center. [https://coronavirus.jhu.edu/us-](https://coronavirus.jhu.edu/us-map)
312 [map](https://coronavirus.jhu.edu/us-map). Accessed.
- 313 2. El-Boghdady K, Cook TM, Goodacre T, et al. SARS-CoV-2 infection, COVID-19
314 and timing of elective surgery: A multidisciplinary consensus statement on behalf
315 of the Association of Anaesthetists, the Centre for Peri-operative Care, the
316 Federation of Surgical Specialty Associations, the Royal College of Anaesthetists
317 and the Royal College of Surgeons of England. *Anaesthesia*. 2021;76(7):940-
318 946.
- 319 3. Collaborative CO. Outcomes and Their State-level Variation in Patients
320 Undergoing Surgery With Perioperative SARS-CoV-2 Infection in the USA: A
321 Prospective Multicenter Study. *Ann Surg*. 2022;275(2):247-251.
- 322 4. Collaborative CO. Mortality and pulmonary complications in patients undergoing
323 surgery with perioperative SARS-CoV-2 infection: an international cohort study.
324 *Lancet*. 2020;396(10243):27-38.
- 325 5. Deng JZ, Chan JS, Potter AL, et al. The Risk of Postoperative Complications
326 After Major Elective Surgery in Active or Resolved COVID-19 in the United
327 States. *Ann Surg*. 2022;275(2):242-246.
- 328 6. Verhagen NB, Koerber NK, Szabo A, et al. Vaccination Against SARS-CoV-2
329 Decreases Risk of Adverse Events in Patients who Develop COVID-19 Following
330 Cancer Surgery. *Ann Surg Oncol*. 2022:1-4.
- 331 7. Collaborative CO, GlobalSurg C. Timing of surgery following SARS-CoV-2
332 infection: an international prospective cohort study. *Anaesthesia*. 2021;76(6):748-
333 758.
- 334 8. SenthilKumar G, Verhagen NB, Sheriff SA, et al. Preoperative SARS-CoV-2
335 Infection Increases Risk of Early Postoperative Cardiovascular Complications
336 Following Non-Cardiac Surgery. *American Journal of Physiology - Heart and*
337 *Circulatory Physiology*. 2023;Accepted. In Press.
- 338 9. Al Ani A, Tahtamoni R, Mohammad Y, Al-Ayoubi F, Haider N, Al-Mashhadi A.
339 Impacts of severity of Covid-19 infection on the morbidity and mortality of surgical
340 patients. *Ann Med Surg (Lond)*. 2022;79:103910.
- 341 10. Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort
342 Collaborative (N3C): Rationale, design, infrastructure, and deployment. *J Am*
343 *Med Inform Assoc*. 2021;28(3):427-443.
- 344 11. Characterisation WHOWGotC, Management of C-i. A minimal common outcome
345 measure set for COVID-19 clinical research. *Lancet Infect Dis*. 2020;20(8):e192-
346 e197.
- 347 12. Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical Characterization and
348 Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using
349 Data From the US National COVID Cohort Collaborative. *JAMA Netw Open*.
350 2021;4(7):e2116901.
- 351 13. ASA and APSF Joint Statement on Elective Surgery/Procedures and Anesthesia
352 for Patients after COVID-19 Infection. 2022. [https://www.asahq.org/about-](https://www.asahq.org/about-asa/newsroom/news-releases/2022/02/asa-and-apsf-joint-statement-on-elective-surgery-procedures-and-anesthesia-for-patients-after-covid-19-infection)
353 [asa/newsroom/news-releases/2022/02/asa-and-apsf-joint-statement-on-elective-](https://www.asahq.org/about-asa/newsroom/news-releases/2022/02/asa-and-apsf-joint-statement-on-elective-surgery-procedures-and-anesthesia-for-patients-after-covid-19-infection)
354 [surgery-procedures-and-anesthesia-for-patients-after-covid-19-infection](https://www.asahq.org/about-asa/newsroom/news-releases/2022/02/asa-and-apsf-joint-statement-on-elective-surgery-procedures-and-anesthesia-for-patients-after-covid-19-infection).

- 355 14. Verheij RA, Curcin V, Delaney BC, McGilchrist MM. Possible Sources of Bias in
356 Primary Care Electronic Health Record Data Use and Reuse. *J Med Internet*
357 *Res.* 2018;20(5):e185.
358

359 **TABLES AND FIGURES**


360 **Table 1. Patient characteristics and 30-day postoperative adverse outcomes in**
 361 **patients with and without preoperative COVID-19**
 362

Characteristics	No Hx of COVID-19 (N = 349,676), No. (%)	Hx of COVID-19 (N = 37,354), No. (%)	P value
Patient Characteristics			
Age, years			
Median, (Q1-Q3)	63 (52, 72)	61 (49, 70)	<0.001
18-29	15166 (4.3%)	1625 (4.4%)	<0.001
30-49	60828 (17%)	7734 (21%)	
50-64	111160 (32%)	12838 (34%)	
65+	162522 (46%)	15157 (41%)	
Sex			<0.001
Female	190052 (54%)	‡20952 (≈56%)	
Male	159505 (46%)	‡16399 (≈44%)	
Missing or Unknown	119 (<0.1%)	20 or fewer	
Race and Ethnicity			<0.001
Non-Hispanic White	257334 (74%)	25833 (69%)	
Non-Hispanic Black	42740 (12%)	4867 (13%)	
Non-Hispanic Asian	8395 (2.4%)	810 (2.2%)	
Hispanic	21325 (6.1%)	3625 (9.1%)	
Other or Unknown	19930 (5.7%)	2403 (6.4%)	
Smoking Status			<0.001
Nonsmoker	304141 (86%)	33151 (89%)	
Current or Former Smoker	47716 (14%)	4203 (11%)	
Charlson Comorbidity Index (CCI)			<0.001
0	72432 (21%)	6772 (18%)	
1	42341 (12%)	4412 (12%)	
2	63704 (18%)	6343 (17%)	
3	38900 (11%)	4275 (11%)	
4+	132299 (38%)	15552 (42%)	
Comorbidities			
CKD	22374 (6.4%)	3862 (10%)	<0.001
CHF	20816 (6.0%)	3454 (9.2%)	<0.001
COPD	21089 (6.0%)	3134 (8.4%)	<0.001
Coronary Artery Disease	39221 (11%)	5852 (16%)	<0.001
Depression	35956 (10%)	5875 (16%)	<0.001
Diabetes	41584 (12%)	7144 (19%)	<0.001
GERD	58830 (17%)	9432 (25%)	<0.001

Hypertension	100981 (29%)	14669 (39%)	<0.001
Liver Disease	5730 (1.6%)	977 (2.6%)	<0.001
Obesity	51446 (15%)	8920 (24%)	<0.001
Relative Risk of Surgery			0.058
Low Risk	134385 (38%)	14364 (38%)	
Medium Risk	166702 (48%)	17642 (47%)	
High Risk	48589 (14%)	5348 (14%)	
Vaccine Status			<0.001
Fully Vaccinated	48441 (14%)	5381 (14%)	
Non-Fully Vaccinated	301235 (86%)	31973 (86%)	
30-day postoperative adverse outcomes			
Composite Adverse Event	75075 (21.5%)	8493 (22.7%)	<0.001
Mortality	4791 (1.4%)	666 (1.8%)	<0.001
Hospital Readmission	38175 (11%)	4248 (11%)	0.008
Any Non-Fatal Complication	73555 (21%)	8257 (22%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	1020 (2.7%)	0.13
Cardiac Arrhythmia	34326 (9.8%)	3752 (10%)	0.16
Deep Vein Thrombosis	4648 (1.3%)	532 (1.4%)	0.13
Pneumonia	9623 (2.8%)	1093 (2.9%)	0.053
Pulmonary Embolism	4296 (1.2%)	519 (1.4%)	0.008
Renal Failure	22488 (6.4%)	2592 (6.9%)	<0.001
Respiratory Failure	18862 (5.4%)	2017 (5.4%)	0.97
Sepsis	10244 (2.9%)	1188 (3.2%)	0.007
Urinary Tract Infection	9662 (2.8%)	1045 (2.8%)	0.71

363 ‡ To comply with N3C policy, counts below 20 are displayed as <20 and additional
364 values were skewed by up to 5 in order to render it impossible to back-calculate
365 precise counts in the 'Missing or Unknown' category. Hx: history; CKD: chronic
366 kidney disease; CHF: congestive heart failure; COPD: chronic obstructive
367 pulmonary disease; GERD: gastroesophageal reflux disease.
368
369
370


371 **Figure 1.** Multivariable regression assessing the association between prior history of
 372 COVID-19 and composite 30-day postoperative adverse event. Hx: history; CCI:
 373 Charlson Comorbidity Index; aOR: adjusted odds ratio (with 95% confidence interval).
 374



375
 376

377

378 **Figure 2.** Multivariable regression assessing the association between timing of infection
379 relative to surgery and 30-day postoperative adverse events. All models adjusted for
380 age, sex, race and ethnicity, smoking status, comorbid disease, and relative risk of
381 surgery. aOR: adjusted odds ratio (with 95% confidence interval).
382




383

384

385

386


387 **Figure 3.** Multivariable regression assessing the association between COVID-19
388 disease severity and 30-day postoperative adverse outcomes. All models adjusted for
389 age, sex, race and ethnicity, smoking status, comorbid disease, and relative risk of
390 surgery. aOR: adjusted odds ratio (with 95% confidence interval).
391



392

393


394 **Figure 4.** The interplay between timing of surgery and COVID-19 disease severity in
 395 influencing odds of composite 30-day postoperative adverse events. All models
 396 adjusted for age, sex, race and ethnicity, smoking status, Charlson Comorbidity Index,
 397 and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence interval).
 398



399

400

401 **Figure 5.** Multivariable regression assessing the association between full vaccination in
402 patients with a history of COVID-19 and 30-day postoperative adverse events. All
403 models adjusted for age, sex, race and ethnicity, smoking status, Charlson Comorbidity
404 Index, and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence
405 interval).
406



407
408
409
410

411 **SUPPLEMENTARY DATA**

412

413 **Supplemental Table 1: Surgical Procedures and associated risk**

414

Procedure Name	Surgery N=387,030 (%)	SNOMED Code
Low Risk		
Hip Arthroplasty	5480 (1.4%)	52734007
Knee Arthroplasty	6034 (1.6%)	609588000
Laminectomy	44462 (11%)	387731002
Mastectomy	75714 (20%)	69031006
Prostatectomy	17059 (4.4%)	90470006
Medium Risk		
Aortic Aneurysm Repair	4881 (1.3%)	233370007
Colectomy	46059 (12%)	23968004
Craniectomy	29201 (7.5%)	36910002
Gastrectomy	7903 (2.0%)	53442002
Lung Excision	17353 (4.5%)	119746007
Spinal Arthrodesis	78947 (20%)	55705006
High Risk		
Coronary Artery Bypass Graft	37492 (9.7%)	232717009
Esophagectomy	1538 (0.4%)	45900003
Hepatectomy	8495 (2.2%)	107963000
Pancreatectomy	6412 (1.7%)	33149006

415

416

417

418 **Supplemental Table 2: Patient comorbidities**

419

Preoperative Comorbidities	SNOMED Codes
Chronic Kidney Disease	709044004
Chronic Obstructive Pulmonary Disease	13645005
Coronary Artery Disease	53741008
Depression	370143000
Diabetes	73211009
Gastroesophageal Reflux Disease	235595009
Heart Failure	84114007
Hypertension	59621000
Liver Disease	328383001
Obesity	414916001

420

421

422 **Supplemental Table 3: Postoperative Complications**

423

Postoperative Complications	SNOMED Codes
Acute Myocardial Infarction	57054005
Cardiac Arrhythmia	698247007
Deep Vein Thrombosis	128053003
Pneumonia	233604007
Pulmonary Embolism	59282003
Renal Failure	42399005
Respiratory Failure	409622000
Sepsis	91302008
Urinary Tract Infection	68566005

424

425

426

427 **Supplemental Table 4. Comparison of 30-day postoperative adverse events based**
 428 **on surgical timing relative to COVID-19**
 429

Outcomes	No History of COVID-19 (N = 352,947)	0–4 Weeks Post-COVID-19 (N = 7,425)	4–8 Weeks Post-COVID-19 (N = 3,936)	8–12 Weeks Post-COVID-19 (N = 2,604)	12+ Weeks Post-COVID-19 (N = 23,389)	P value
Mortality	4791 (1.4%)	246 (3.3%)	83 (2.1%)	47 (1.8%)	290 (1.2%)	<0.001
LOS	2 (0, 6)	4 (1, 8)	2 (0, 6)	3 (0, 6)	2 (0, 5)	<0.001
Hospital Readmission	38175 (11%)	848 (11%)	458 (12%)	318 (12%)	2622 (11%)	0.057
Any Non-Fatal Complication	73555 (21%)	1914 (26%)	890 (23%)	625 (24%)	4828 (21%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	271 (3.6%)	100 (2.5%)	57 (2.2%)	592 (2.5%)	<0.001
Cardiac Arrhythmia	34326 (9.8%)	803 (11%)	409 (10%)	286 (11%)	2254 (9.6%)	0.006
Deep Vein Thrombosis	4648 (1.3%)	142 (1.9%)	57 (1.4%)	46 (1.8%)	287 (1.2%)	<0.001
Pneumonia	9623 (2.8%)	348 (4.7%)	131 (3.3%)	95 (3.6%)	519 (2.2%)	<0.001
Pulmonary Embolism	4296 (1.2%)	137 (1.8%)	58 (1.5%)	35 (1.3%)	289 (1.2%)	<0.001
Renal Failure	22488 (6.4%)	654 (8.8%)	288 (7.3%)	204 (7.8%)	1446 (6.2%)	<0.001
Respiratory Failure	18862 (5.4%)	655 (8.8%)	197 (5.0%)	164 (6.3%)	1001 (4.3%)	<0.001
Sepsis	10244 (2.9%)	346 (4.7%)	134 (3.4%)	95 (3.6%)	613 (2.6%)	<0.001
Urinary Tract Infection	9662 (2.8%)	208 (2.8%)	110 (2.8%)	88 (3.4%)	639 (2.7%)	0.43

430
431

432 **Supplemental Table 5.** Multivariable regression assessing the impact of timing of
 433 infection relative to surgery on risk on composite and specific 30-day postoperative
 434 adverse outcomes. All models adjusted for age, sex, race and ethnicity, smoking status,
 435 and relative risk of surgery.
 436

	0–4 weeks (N = 7,425)		4–8 weeks (N = 3,936)		8–12 weeks (N = 2,604)		12+ Weeks (N = 23,389)	
Composite 30-day postoperative outcome	1.27	[1.20-1.35]	1.14	[1.05-1.24]	1.16	[1.05-1.28]	1.01	[0.98-1.05]
Mortality	2.34	[2.05-2.67]	1.57	[1.25-1.95]	1.22	[0.90-1.62]	0.92	[0.81-1.03]
Composite Non-fatal Complications	1.22	[1.15-1.29]	1.10	[1.01-1.20]	1.14	[1.03-1.26]	1.01	[0.98-1.05]
Hospital Readmission	0.99	[0.92-1.07]	1.02	[0.92-1.13]	1.06	[0.94-1.19]	1.01	[0.97-1.05]
Myocardial Infarction	1.13	[0.99-1.29]	0.93	[0.75-1.14]	0.73	[0.55-0.96]	1.06	[0.96-1.15]
Cardiac Arrhythmia	1.04	[0.96-1.13]	1.11	[1.00-1.24]	1.15	[1.00-1.31]	1.09	[1.04-1.15]
Deep Vein Thrombosis	1.33	[1.12-1.57]	1.04	[0.79-1.34]	1.21	[0.89-1.61]	0.88	[0.78-0.99]
Pneumonia	1.60	[1.43-1.79]	1.21	[1.01-1.44]	1.24	[1.00-1.52]	0.81	[0.74-0.88]
Pulmonary Embolism	1.44	[1.20-1.70]	1.17	[0.89-1.50]	1.01	[0.71-1.39]	0.96	[0.85-1.08]
Renal Failure	1.28	[1.17-1.39]	1.13	[0.99-1.27]	1.12	[0.96-1.30]	0.94	[0.89-1.00]
Respiratory Failure	1.53	[1.40-1.66]	0.90	[0.77-1.04]	1.09	[0.92-1.28]	0.80	[0.74-0.85]
Sepsis	1.52	[1.36-1.69]	1.14	[0.95-1.36]	1.15	[0.92-1.40]	0.87	[0.80-0.94]
Urinary Tract Infection	1.01	[0.87-1.15]	1.02	[0.84-1.23]	1.17	[0.94-1.44]	0.97	[0.90-1.05]

437
 438

439 **Supplemental Table 6. Comparison of specific 30-day postoperative adverse**
 440 **events based on COVID-19 Severity.**
 441

Postoperative Complications	No History of COVID-19 (N = 351,857)	Mild Outpatient WHO Severity 1–3 (N = 31,677)	Moderate Hospitalized without invasive ventilation WHO Severity 4–6 (N= 5,009)	Severe Hospitalized with invasive ventilation or ECMO WHO Severity 7–9 (N= 655)	P value
Mortality	4791 (1.4%)	403 (1.3%)	169 (3.4%)	94 (14%)	<0.001
LOS	2 (0, 6)	2 (0, 5)	4 (1, 9)	12 (4, 29)	<0.001
Hospital Readmission	38175 (11%)	3293 (10%)	832 (17%)	121 (18%)	<0.001
Any Non-Fatal Complication	73555 (21%)	6110 (19%)	1746 (35%)	396 (60%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	723 (2.3%)	243 (4.9%)	53 (8.1%)	<0.001
Cardiac Arrhythmia	34326 (9.8%)	2856 (9.0%)	751 (15%)	142 (22%)	<0.001
Deep Vein Thrombosis	4648 (1.3%)	364 (1.1%)	126 (2.5%)	42 (6.4%)	<0.001
Pneumonia	9623 (2.8%)	704 (2.2%)	249 (5.0%)	138 (21%)	<0.001
Pulmonary Embolism	4296 (1.2%)	388 (1.2%)	99 (2.0%)	32 (4.9%)	<0.001
Renal Failure	22488 (6.4%)	1822 (5.8%)	588 (12%)	180 (27%)	<0.001
Respiratory Failure	18862 (5.4%)	1338 (4.2%)	448 (8.9%)	228 (35%)	<0.001
Sepsis	10244 (2.9%)	764 (2.4%)	271 (5.4%)	151 (23%)	<0.001
Urinary Tract Infection	9662 (2.8%)	791 (2.5%)	214 (4.3%)	39 (6.0%)	<0.001

442

443 **Supplemental Table 7.** Multivariable regression assessing the impact of COVID-19
 444 disease severity on composite and specific 30-day postoperative adverse outcomes. All
 445 models adjusted for age, sex, race and ethnicity, smoking status, and relative risk of
 446 surgery.
 447

	Mild (N = 31,677)	Moderate (N = 5,009)	Severe (N = 655)
Composite 30-day postoperative outcome	0.96 [0.93-1.00]	1.52 [1.43-1.62]	4.76 [4.01-5.68]
Mortality	1.00 [0.90-1.11]	1.77 [1.51-2.07]	7.49 [5.93-9.35]
Composite Non-fatal Complications	0.96 [0.93-0.99]	1.47 [1.38-1.57]	4.08 [3.44-4.84]
Hospital Readmission	0.96 [0.92-1.00]	1.26 [1.17-1.36]	1.20 [0.98-1.46]
Myocardial Infarction	0.94 [0.86-1.02]	1.31 [1.13-1.50]	2.02 [1.46-2.73]
Cardiac Arrhythmia	1.03 [0.98-1.07]	1.27 [1.17-1.38]	2.02 [1.64-2.47]
Deep Vein Thrombosis	0.87 [0.78-0.97]	1.37 [1.13-1.63]	3.01 [2.16-4.08]
Pneumonia	0.85 [0.79-0.92]	1.30 [1.14-1.48]	5.53 [4.53-6.70]
Pulmonary Embolism	1.01 [0.91-1.12]	1.19 [0.96-1.45]	2.56 [1.75-3.60]
Renal Failure	0.93 [0.88-0.98]	1.28 [1.17-1.40]	3.24 [2.69-3.89]
Respiratory Failure	0.82 [0.77-0.87]	1.20 [1.08-1.32]	5.71 [4.81-6.76]
Sepsis	0.85 [0.78-0.91]	1.33 [1.17-1.51]	5.91 [4.88-7.12]
Urinary Tract Infection	0.93 [0.86-1.00]	1.25 [1.08-1.43]	1.72 [1.22-2.36]

448
 449
 450

451 **Supplemental Table 8.** Comparison of specific 30-day postoperative adverse events
452 based on vaccination in patients with COVID-19.

Postoperative Complications	Non-Fully Vaccinated (N = 31,973), No. (%)	Fully Vaccinated (N = 5,381), No. (%)	P value
Mortality	585 (1.8%)	81 (1.5%)	0.11
LOS	2 (0, 6)	3 (0, 6)	0.014
Hospital Readmission	3644 (11%)	604 (11%)	0.73
Any Non-Fatal Complication	7072 (22%)	1185 (22%)	0.89
Acute Myocardial Infarction	892 (2.8%)	128 (2.4%)	0.10
Cardiac Arrhythmia	3172 (9.9%)	580 (11%)	0.056
Deep Vein Thrombosis	465 (1.5%)	67 (1.2%)	0.26
Pneumonia	970 (3.0%)	123 (2.3%)	0.003
Pulmonary Embolism	434 (1.4%)	85 (1.6%)	0.22
Renal Failure	2245 (7.0%)	347 (6.4%)	0.13
Respiratory Failure	1792 (5.6%)	225 (4.2%)	<0.001
Sepsis	1042 (3.3%)	146 (2.7%)	0.039
Urinary Tract Infection	873 (2.7%)	172 (3.2%)	0.061

453

454

455

456

457 **DISCLAIMER**

458 The N3C Publication committee confirmed that this manuscript (MSID: 1004.67) is in
459 accordance with N3C data use and attribution policies; however, the content is solely the
460 responsibility of the authors and does not necessarily represent the official views of the NIH.
461 Authorship was determined using ICMJE recommendations.

462
463 **ACKNOWLEDGEMENT**

464 The analyses described in this publication were conducted under the DUR RP-A39709 and IRB
465 #PRO00042159 with data or tools accessed through the NCATS N3C Data Enclave
466 covid.cd2h.org/enclave and supported by CD2H - The National COVID Cohort Collaborative
467 (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306. The project
468 described was supported by the National Center for Advancing Translational Sciences, National
469 Institutes of Health, Award Number UL1 TR001436 and 3UL1TR001436-08S3. Additional
470 funding support provided by Advancing a Healthier Wisconsin Endowment. This research was
471 possible because of the patients whose information is included within the data from participating
472 organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas)
473 who have contributed to the on-going development of this community resource
474 (<https://doi.org/10.1093/jamia/ocaa196>).

475
476 We gratefully acknowledge the following core contributors to N3C:

477 Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit
478 Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin,
479 Anita Walden, Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks,
480 Brijesh Patel, Caleb Alexander, Carolyn Bramante, Cavin Ward-Caviness, Charisse Madlock-
481 Brown, Christine Suver, Christopher Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff
482 Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Don Brown,
483 Eilis Boudreau, Elaine Hill, Elizabeth Zampino, Emily Carlson Marti, Emily R. Pfaff, Evan
484 French, Farrukh M Koraisly, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold
485 Lehmann, Heidi Spratt, Hemalkumar Mehta, Hongfang Liu, Hythem Sidky, J.W. Awori Hayanga,
486 Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Islam, Jin Ge, Joel Gagnier, Joel
487 H. Saltz, Joel Saltz, Johanna Loomba, John Buse, Jomol Mathew, Joni L. Rutter, Julie A.
488 McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M.
489 Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Dwain Cato, Kimberly Murray, Kristin
490 Kostka, Lavance Northington, Lee Allan Pyles, Leonie Misquitta, Lesley Cottrell, Lili Portilla,
491 Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Mary Morrison Saltz, Matvey B.
492 Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple-O'Connor, Michael G. Kurilla,
493 Michele Morris, Nabeel Qureshi, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan,
494 Patricia A. Francis, Penny Wung Burgoon, Peter Robinson, Philip R.O. Payne, Rafael Fuentes,
495 Randeep Jawa, Rebecca Erwin-Cohen, Rena Patel, Richard A. Moffitt, Richard L. Zhu, Rishi
496 Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel
497 Bozette, Sandeep Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko
498 Setoguchi, Stephanie S. Hong, Steve Johnson, Tellen D. Bennett, Tiffany Callahan, Umit
499 Topaloglu, Usman Sheikh, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wendy
500 Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang. Details of
501 contributions available at covid.cd2h.org/core-contributors

502
503 The following institutions whose data is released or pending:
504 Available: Advocate Health Care Network — UL1TR002389: The Institute for Translational
505 Medicine (ITM) • Boston University Medical Campus — UL1TR001430: Boston University
506 Clinical and Translational Science Institute • Brown University — U54GM115677: Advance
507 Clinical Translational Research (Advance-CTR) • Carilion Clinic — UL1TR003015: iTHRIV

508 Integrated Translational health Research Institute of Virginia • Charleston Area Medical Center
509 — U54GM104942: West Virginia Clinical and Translational Science Institute (WVCTSI) •
510 Children's Hospital Colorado — UL1TR002535: Colorado Clinical and Translational Sciences
511 Institute • Columbia University Irving Medical Center — UL1TR001873: Irving Institute for
512 Clinical and Translational Research • Duke University — UL1TR002553: Duke Clinical and
513 Translational Science Institute • George Washington Children's Research Institute —
514 UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN) •
515 George Washington University — UL1TR001876: Clinical and Translational Science Institute at
516 Children's National (CTSA-CN) • Indiana University School of Medicine — UL1TR002529:
517 Indiana Clinical and Translational Science Institute • Johns Hopkins University —
518 UL1TR003098: Johns Hopkins Institute for Clinical and Translational Research • Loyola
519 Medicine — Loyola University Medical Center • Loyola University Medical Center —
520 UL1TR002389: The Institute for Translational Medicine (ITM) • Maine Medical Center —
521 U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network •
522 Massachusetts General Brigham — UL1TR002541: Harvard Catalyst • Mayo Clinic Rochester
523 — UL1TR002377: Mayo Clinic Center for Clinical and Translational Science (CCaTS) • Medical
524 University of South Carolina — UL1TR001450: South Carolina Clinical & Translational
525 Research Institute (SCTR) • Montefiore Medical Center — UL1TR002556: Institute for Clinical
526 and Translational Research at Einstein and Montefiore • Nemours — U54GM104941: Delaware
527 CTR ACCEL Program • NorthShore University HealthSystem — UL1TR002389: The Institute for
528 Translational Medicine (ITM) • Northwestern University at Chicago — UL1TR001422:
529 Northwestern University Clinical and Translational Science Institute (NUCATS) • OCHIN — INV-
530 018455: Bill and Melinda Gates Foundation grant to Sage Bionetworks • Oregon Health &
531 Science University — UL1TR002369: Oregon Clinical and Translational Research Institute •
532 Penn State Health Milton S. Hershey Medical Center — UL1TR002014: Penn State Clinical and
533 Translational Science Institute • Rush University Medical Center — UL1TR002389: The Institute
534 for Translational Medicine (ITM) • Rutgers, The State University of New Jersey —
535 UL1TR003017: New Jersey Alliance for Clinical and Translational Science • Stony Brook
536 University — U24TR002306 • The Ohio State University — UL1TR002733: Center for Clinical
537 and Translational Science • The State University of New York at Buffalo — UL1TR001412:
538 Clinical and Translational Science Institute • The University of Chicago — UL1TR002389: The
539 Institute for Translational Medicine (ITM) • The University of Iowa — UL1TR002537: Institute for
540 Clinical and Translational Science • The University of Miami Leonard M. Miller School of
541 Medicine — UL1TR002736: University of Miami Clinical and Translational Science Institute •
542 The University of Michigan at Ann Arbor — UL1TR002240: Michigan Institute for Clinical and
543 Health Research • The University of Texas Health Science Center at Houston —
544 UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • The University of Texas
545 Medical Branch at Galveston — UL1TR001439: The Institute for Translational Sciences • The
546 University of Utah — UL1TR002538: Uhealth Center for Clinical and Translational Science •
547 Tufts Medical Center — UL1TR002544: Tufts Clinical and Translational Science Institute •
548 Tulane University — UL1TR003096: Center for Clinical and Translational Science • University
549 Medical Center New Orleans — U54GM104940: Louisiana Clinical and Translational Science
550 (LA CaTS) Center • University of Alabama at Birmingham — UL1TR003096: Center for Clinical
551 and Translational Science • University of Arkansas for Medical Sciences — UL1TR003107:
552 UAMS Translational Research Institute • University of Cincinnati — UL1TR001425: Center for
553 Clinical and Translational Science and Training • University of Colorado Denver, Anschutz
554 Medical Campus — UL1TR002535: Colorado Clinical and Translational Sciences Institute •
555 University of Illinois at Chicago — UL1TR002003: UIC Center for Clinical and Translational
556 Science • University of Kansas Medical Center — UL1TR002366: Frontiers: University of
557 Kansas Clinical and Translational Science Institute • University of Kentucky — UL1TR001998:
558 UK Center for Clinical and Translational Science • University of Massachusetts Medical School

559 Worcester — UL1TR001453: The UMass Center for Clinical and Translational Science
560 (UMCCTS) • University of Minnesota — UL1TR002494: Clinical and Translational Science
561 Institute • University of Mississippi Medical Center — U54GM115428: Mississippi Center for
562 Clinical and Translational Research (CCTR) • University of Nebraska Medical Center —
563 U54GM115458: Great Plains IDEA-Clinical & Translational Research • University of North
564 Carolina at Chapel Hill — UL1TR002489: North Carolina Translational and Clinical Science
565 Institute • University of Oklahoma Health Sciences Center — U54GM104938: Oklahoma Clinical
566 and Translational Science Institute (OCTSI) • University of Rochester — UL1TR002001: UR
567 Clinical & Translational Science Institute • University of Southern California — UL1TR001855:
568 The Southern California Clinical and Translational Science Institute (SC CTSI) • University of
569 Vermont — U54GM115516: Northern New England Clinical & Translational Research (NNE-
570 CTR) Network • University of Virginia — UL1TR003015: iTHRIV Integrated Translational health
571 Research Institute of Virginia • University of Washington — UL1TR002319: Institute of
572 Translational Health Sciences • University of Wisconsin-Madison — UL1TR002373: UW
573 Institute for Clinical and Translational Research • Vanderbilt University Medical Center —
574 UL1TR002243: Vanderbilt Institute for Clinical and Translational Research • Virginia
575 Commonwealth University — UL1TR002649: C. Kenneth and Dianne Wright Center for Clinical
576 and Translational Research • Wake Forest University Health Sciences — UL1TR001420: Wake
577 Forest Clinical and Translational Science Institute • Washington University in St. Louis —
578 UL1TR002345: Institute of Clinical and Translational Sciences • Weill Medical College of Cornell
579 University — UL1TR002384: Weill Cornell Medicine Clinical and Translational Science Center •
580 West Virginia University — U54GM104942: West Virginia Clinical and Translational Science
581 Institute (WVCTSI)
582 Submitted: Icahn School of Medicine at Mount Sinai — UL1TR001433: ConduITS Institute for
583 Translational Sciences • The University of Texas Health Science Center at Tyler —
584 UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • University of California,
585 Davis — UL1TR001860: UC Davis Health Clinical and Translational Science Center • University
586 of California, Irvine — UL1TR001414: The UC Irvine Institute for Clinical and Translational
587 Science (ICTS) • University of California, Los Angeles — UL1TR001881: UCLA Clinical
588 Translational Science Institute • University of California, San Diego — UL1TR001442: Altman
589 Clinical and Translational Research Institute • University of California, San Francisco —
590 UL1TR001872: UCSF Clinical and Translational Science Institute
591 Pending: Arkansas Children's Hospital — UL1TR003107: UAMS Translational Research
592 Institute • Baylor College of Medicine — None (Voluntary) • Children's Hospital of Philadelphia
593 — UL1TR001878: Institute for Translational Medicine and Therapeutics • Cincinnati Children's
594 Hospital Medical Center — UL1TR001425: Center for Clinical and Translational Science and
595 Training • Emory University — UL1TR002378: Georgia Clinical and Translational Science
596 Alliance • HonorHealth — None (Voluntary) • Loyola University Chicago — UL1TR002389: The
597 Institute for Translational Medicine (ITM) • Medical College of Wisconsin — UL1TR001436:
598 Clinical and Translational Science Institute of Southeast Wisconsin • MedStar Health Research
599 Institute — UL1TR001409: The Georgetown-Howard Universities Center for Clinical and
600 Translational Science (GHUCCTS) • MetroHealth — None (Voluntary) • Montana State
601 University — U54GM115371: American Indian/Alaska Native CTR • NYU Langone Medical
602 Center — UL1TR001445: Langone Health's Clinical and Translational Science Institute •
603 Ochsner Medical Center — U54GM104940: Louisiana Clinical and Translational Science (LA
604 CaTS) Center • Regenstrief Institute — UL1TR002529: Indiana Clinical and Translational
605 Science Institute • Sanford Research — None (Voluntary) • Stanford University —
606 UL1TR003142: Spectrum: The Stanford Center for Clinical and Translational Research and
607 Education • The Rockefeller University — UL1TR001866: Center for Clinical and Translational
608 Science • The Scripps Research Institute — UL1TR002550: Scripps Research Translational
609 Institute • University of Florida — UL1TR001427: UF Clinical and Translational Science Institute

610 • University of New Mexico Health Sciences Center — UL1TR001449: University of New Mexico
611 Clinical and Translational Science Center • University of Texas Health Science Center at San
612 Antonio — UL1TR002645: Institute for Integration of Medicine and Science • Yale New Haven
613 Hospital — UL1TR001863: Yale Center for Clinical Investigation
614